Unaudited Condensed Consolidated Balance Sheets $ in Millions	Mar. 31, 2026 USD ($)	Dec. 31, 2025 USD ($)
Current Assets
Cash and cash equivalents	$ 140,324	$ 681,480
Restricted cash		645,505
Short-term investments	62,185	64,354
Prepaid expense and other current assets	250,017	346,616
Total Current Assets	648,848	2,501,343
Property and equipment, net	12,822,985	12,835,409
Operating lease right-of-use assets	1,826,905	1,913,278
Long-term investments	1,845,770	1,878,465
Prepayment for long-term investments	1,789,703	1,124,842
Prepayment for asset acquisition	691,900	691,900
Other non-current assets	106,417	116,966
Total Assets	19,732,528	21,062,203
Current Liabilities
Short-term bank and other loans	88,737	755,512
Accrued expenses and other current liabilities	4,154,364	4,161,629
Contract liabilities	12,600	12,600
Operating lease liabilities	332,252	317,557
Taxes payable	5,888	11,964
Convertible notes payable – third parties	559,010	559,010
Total Current Liabilities	5,393,128	6,163,976
Operating lease liability – non-current	1,510,943	1,600,747
Total Liabilities	6,904,071	7,764,723
COMMITMENTS AND CONTINGENCIES
Equity
Preferred stock, $0.001 par value, 20,000,000 authorized, nil shares issued and outstanding
Common stock, $0.001 par value, 100,000,000 authorized, 25,767,664 and 25,053,193 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	25,767	25,053
Stock to be issued	422,492	359,000
Additional paid-in capital	97,152,918	96,008,258
Accumulated deficit	(78,418,603)	(76,858,361)
Accumulated other comprehensive income	499,650	487,602
Treasury stock	(8,909,691)	(8,909,691)
Total Stockholders’ equity	10,772,533	11,111,861
Noncontrolling interest	2,055,924	2,185,619
Total Equity	12,828,457	13,297,480
Total Liabilities and Equity	19,732,528	21,062,203
Related Party
Current Assets
Due from related parties	167,324	763,388
Convertible notes receivable – related parties	28,998
Current Liabilities
Due to related parties	277	105,704
Convertible notes payable – third parties		240,000
Convertible notes payable – related parties	240,000	240,000
Third Parties
Current Liabilities
Convertible notes payable – third parties	$ 559,010	$ 559,010

ABVC BIOPHARMA, INC. 10-Q